Premarket Biotech Digest – $IMDZ to start new trial, $ANIK reports approval, $AMGN announces new collaboration

By |October 17th, 2017|Digest|

Aimmune Therapeutics ($AIMT) announced its new clinical trial collaboration with Regeneron Pharmaceuticals and Sanofi for testing AR101 with adjunctive DUPIXENT (dupilumab) in patients with peanut allergy. The planned Phase 2 study is expected to start next year. It will involve examining patients' desensitization to [...]

AbbVie stock to retain momentum on the back of drug approval and Humira case $ABBV

By |October 13th, 2017|Monthly Investment Ideas|

AbbVie Inc. ($ABBV) stock continues its positive run on the back of several positive events. The company is working towards making its portfolio more diverse and to reduce its reliance on its star performer Humira. It recently announced the FDA approval of its Mavyret for treating Hepatitis C virus genotype [...]

Premarket Biotech Digest – $KTOV buys stake, $JNJ reports positive results, $NVS receives CE mark

By |October 9th, 2017|Digest|

Kitov Pharmaceuticals ($KTOV) announced that it has acquired an additional 27% stake in privately held TyrNovo, a developer of small molecule oncology drugs. The company now controls nearly 92 percent stake in TyrNovo. In this latest transaction with a group of minority shareholders, Kitov [...]

Acadia Pharmaceuticals boosts position in Parkinson’s disease market ($ACAD)

By |October 6th, 2017|Monthly Investment Ideas|

Acadia Pharmaceuticals Inc. ($ACAD) is one of the most prominent players in Parkinson’s disease market. The company also has presence in other related markets including Alzheimer’s. Acadia’s recently reported strong financial numbers for its second quarter. The company’s net loss for the quarter stood at $0.55 per share, lower than [...]

Premarket Biotech Digest – $VICL stock shoots up, $MNK announces new deal, $AST announces positive results

By |October 3rd, 2017|Digest|

Vical Inc. ($VICL) announced that the FDA has advised the company that a single successful Phase 2 clinical trial may be sufficient to support approval of antifungal VL-2397 under Limited Use Indication (LUI) status. The company plans to start its mid-stage study this quarter [...]

Shire Plc stock looks attractive ahead of EU decision on eye drug $SHPG

By |September 29th, 2017|Monthly Investment Ideas|

Shire Plc ($SHPG) stock showed strong recovery after hitting its 52 weeks low. The stock’s strong movements indicate the reversal of downward trend and the stock looks attractive at current price point. The company is currently in the process of its corporate restructuring, which is expected to result in more [...]

Premarket Biotech Digest – $BTX reports positive data, $CPIX launches Totect, $JAGX inks new deal

By |September 26th, 2017|Digest|

ProQR Therapeutics ($PRQR) stock shot up as the company reported positive preliminary results from a Phase 1b clinical trial assessing QR-010 for the treatment of cystic fibrosis (CF) patients with the F508del mutation. QR-010 is an RNA-based oligonucleotide that targets the messenger RNA in [...]

Rigel Pharmaceuticals stock presents strong case ahead of FDA decision $RIGL

By |September 22nd, 2017|Monthly Investment Ideas|

Rigel Pharmaceuticals Inc. ($RIGL) recently reported receiving the FDA approval of its New Drug Application for Tavalisse in patients suffering from chronic or persistent immune thrombocytopenia. The company used its Phase 3 clinical program data for supporting the application. The data pertains to 163 patients suffering from the condition. The [...]

Premarket Biotech Digest – $FATE starts Phase 2, $OCX reports positive results, $PTIE receives new grant

By |September 19th, 2017|Digest|

Fate Therapeutics ($FATE) announced the start of Phase 2 segment of its Phase 1/2 clinical trial, PROTECT, assessing ProTmune for the prevention of acute graft-versus-host disease (GvHD) in patients with blood cancers undergoing matched unrelated donor hematopoietic cell transplantation. The Phase 2 study will [...]

Ionis Pharmaceuticals makes strong move with new drug filing $IONS

By |September 15th, 2017|Monthly Investment Ideas|

Ionis Pharmaceuticals Inc. ($IONS) took an important step ahead with the recent filing of its New Drug Application (NDA) for volanesorsen, an investigational medicine for the treatment of familial chylomicronemia syndrome. The company has already filed for the approval in the European Union as well. Ionis plans to launch the [...]

Premarket Biotech Digest – $SHPG reports positive results, $TEVA inks an agreement, $NVS files BLA

By |September 12th, 2017|Digest|

CymaBay Therapeutics ($CBAY) announced the grant of Orphan Drug Status to its seladelpar by the European Medicines Agency's Committee for Orphan Medicinal Products. The designation has been granted to seladelpar drug for the treatment of primary biliary cholangitis, a liver disease. The orphan drug [...]

Gilead shows strong prospects in Oncology segment with Kite acquisition $GILD

By |September 7th, 2017|Monthly Investment Ideas|

  Gilead Sciences Inc. ($GILD) recently announced its acquisition of Kite Pharma, giving a major boost to its stock price in the market. The acquisition is important as the merger will allow Gilead to boost its position in oncology segment. It will also fortify the company’s drug pipeline. The company [...]

Premarket Biotech Digest – $INSM reports positive data, $MRK gets EC approval, $LCI receives FDA approval

By |September 5th, 2017|Digest|

Oramed Pharmaceuticals ($ORMP) reported the successful conclusion of its meeting with the FDA with regard to its drug candidate ORMD-0801. The company reported that the FDA gave clear guidance that the regulatory pathway for submission of ORMD-0801 will be a Biologics License Application. This [...]

Premarket Biotech Digest – $IMDZ reports data, $DXTR announced 510(k) clearance, $JNJ terminates collaboration

By |September 1st, 2017|Digest|

Immune Design ($IMDZ) announced interim top line data from a Phase 2 clinical trial assessing the combination of its CMB305 and Roche's TECENTRIQ (atezolizumab) compared to TECENTRIQ alone in 88 soft tissue sarcoma patients. The data showed a treatment effect from CMB305. Data on [...]

Novo Nordisk close to 52 weeks high with new approvals and strong study results $NVO

By |August 31st, 2017|Monthly Investment Ideas|

Novo Nordisk ($NVO) announced a couple of encouraging news as its drug candidates received positive nod from the regulators. The company’s Tresiba, a once a day treatment of adults with diabetes mellitus for improving glycemic control, has been approved by the Canadian regulatory authority. The drug is already approved in [...]

Premarket Biotech Digest – $URGN receives Fast Track Designation, $MDVX receives Australian approval, $AZN inks a new deal

By |August 30th, 2017|Digest|

Tabula Rasa Healthcare ($TRHC) stock perked up as the company announced inking a new deal with CenterLight Healthcare to provide medication risk management services. The company inked the deal through its wholly owned subsidiary CareKinesis. The agreement will be effective from September 1. It [...]

Cara Therapeutics stock to maintain momentum with upcoming catalysts $CARA

By |August 29th, 2017|Monthly Investment Ideas|

Cara Therapeutics Inc. ($CARA) reported its quarterly results. The company announced its net loss for the quarter at $9.3 million, down from a net loss of $13.1 million it had reported for the corresponding quarter of the previous year. On per share basis, the net loss stood at $0.29, down [...]

Premarket Biotech Digest – $NSPR inks new agreement, $AYTU reverse splits stock, $SGMO initiates dosing

By |August 28th, 2017|Digest|

CareDx ($CDNA) stock perked up as the company confirmed Medicare coverage for its AlloSure kidney transplant surveillance test. The coverage will be effective from October 9. The Centers for Medicare and Medicaid Services (CMS) released the final version of the coverage policy issued by [...]

Premarket Biotech Digest – $KMDA receives FDA approval, $LH all clear for acquisition, $KOOL inks new deal

By |August 25th, 2017|Digest|

Kamada Ltd. (NASDAQ:KMDA) stock picked up as the company announced receiving the FDA approval for KEDRAB, its rabies immune globulin. The drug is expected to launched in the US in early 2018. Under the terms of its agreement with Kedrion Biopharma, Kamada holds the [...]

The Medicines Company looks strong ahead of the FDA decisions later this month $MDCO

By |August 24th, 2017|Monthly Investment Ideas|

The Medicines Company ($MDCO) recently reported its second quarter results as the company also provided details about its corporate developments. The Medicines Company’s global net revenue stood at $18.7 million, in comparison to $54.7 million it had reported for the second quarter of the previous year. The company’s net loss [...]

s2Member®